Skip to main content

Tyrosinemia, Type II

Tyrosinemia, Type II

Patient Information

Characteristics

Background and History

Tyrosine is an amino acid, one of numerous building blocks that are needed to make proteins.  Numerous inherited human diseases are the result of gene mutations that in some way impact the metabolism of amino acids. 

Clinical Correlations

This rare disorder results from a deficiency in a liver enzyme needed to convert tyrosine into a useable form.  The result is an accumulation of this amino acid in the blood and cells.  This may lead to growth and mental retardation.  Developmental milestones such as sitting and walking are often delayed.  Elevated, painful lesions on the palms and soles are often present.  The surface of the cornea (windshield of the eye) may become inflamed and irregular causing, pain, redness, sensitivity to light, and excessive tearing.  Sometimes the cornea becomes ulcerated and scarred thereby interfering with vision. 

Genetics

Inheritance

This is an autosomal recessive condition requiring the presence of two mutations.  The parents, who are clinically normal, may each contribute a single mutation to their child who now has the double dose necessary for the disease to appear.  The risk for tyrosinemia II in each of their children is 25%. 

Pedigree

Autosomal recessive

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent.  Carriers with only one mutation, such as the parents, do not have clinical disease.  Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Image
Sample pedigree of autosomal recessive inheritance

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent. Carriers with only one mutation, such as the parents, do not have clinical disease. Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Diagnosis and Prognosis

The diagnosis may be made by a pediatrician through urine and blood tests.  A diet low in protein may decrease the corneal and skin lesions but its impact on the growth and mental deficits is unknown at this time. 

Web Resources

Web Resource Printout Display
http://ghr.nlm.nih.gov/condition/tyrosinemia

Printer Friendly Version: Ctrl/Cmd+P